Kenneth J. Tomecki, MD, discussed the clinical relevance of sexually transmitted diseases to dermatology and outlined what to look for and how to treat various conditions at the 2022 Fall Clinical Dermatology Conference for PAs & NPs.
Sexually transmitted diseases and infections (STDs/STIs) are common health issues in the United States, according to Kenneth J. Tomecki, MD, staff physician in the department of dermatology at the Cleveland Clinic, and past president of the American Academy of Dermatology.1 He cited 2018 data from the Centers for Disease Control and Prevention (CDC) that revealed 1 in 5 people in the United States had an STI. In that year alone, there were 26 million newly acquired STIs, nearly 50% of which were acquired by people aged 15 to 24 years. Nearly $16 billion was spent on direct medial costs.2
In light of these statistics, it is important that physicians expand their knowledge about different STDs and how to treat them, Tomecki said.
Tomecki ended his presentation with key facts about the STDs/STIs in 20223:
Originally published on our sister brand, Dermatology Times.
Disclosure:
Tomecki reported no relevant disclosures.
References:
Having "the talk" with teen patients
June 17th 2022A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.
RSV: 1 year post-tripledemic emergency department update
October 22nd 2023Steven Selbst, MD, provides a quick update on what he has noticed in his hospital when it comes to RSV-associated emergency department visits and how they compare to this time last year, during the "tripledemic." This interview was conducted at the 2023 American Academy of Pediatrics National Conference and Exhibition in Washington DC.
Navigating a complex case of pediatric COVID-19 with immunomodulatory therapies
October 21st 2023Eculizumab and anakinra should be considered in critically ill patients with severe infections that require immunomodulating therapies for life-threatening dysregulation, according to a poster session at the 2023 American Academy of Pediatrics National Conference & Exhibition.